Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1996-04-25
2000-01-25
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
435 721, 436503, 530300, 530324, 530350, A61K 3900, G01N 33567, C07K 200, C07K 500
Patent
active
060175338
ABSTRACT:
This specification relates to the use of peptides having a specific affinity to pituitary adenylate cyclase activating polypeptide (PACAP) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M65 acts as an antagonist to PACAP type 1 receptors.
REFERENCES:
patent: 5637309 (1997-06-01), Tajima et al.
Lerner Ethan A.
Moro Osamu
Ohnuma Manami
Tajima Masahiro
Wakita Kawori
Caputa Anthony C.
Navarro Mark
Shiseido Company Ltd.
The General Hospital Corporation
LandOfFree
Peptides having specific affinity to pituitary adenylate cyclase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides having specific affinity to pituitary adenylate cyclase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides having specific affinity to pituitary adenylate cyclase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2313854